SEC Comment Letter 0000000000-24-008282 to ZeroStack Corp. (ZSTK)

ZeroStack Corp.
Date: July 22, 2024 · CIK: 0001790169 · Accession: 0000000000-24-008282

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 024-12465

Date

July 22, 2024

Author

Clifford Starke

Form

UPLOAD

Company

ZeroStack Corp.

Letter

July 22, 2024 Clifford Starke Chief Executive Officer Flora Growth Corp. 3230 W. Commercial Boulevard, Suite 180 Fort Lauderdale, FL 33309 Re:Flora Growth Corp. Offering Statement on Form 1-A Filed July 16, 2024 File No. 024-12465 Dear Clifford Starke: This is to advise you that we do not intend to review your offering statement. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Richard Raymer, Esq.

Show Raw Text

July 22, 2024
Clifford Starke
Chief Executive Officer
Flora Growth Corp.
3230 W. Commercial Boulevard, Suite 180
Fort Lauderdale, FL 33309
Re:Flora Growth Corp.
Offering Statement on Form 1-A
Filed July 16, 2024
File No. 024-12465
Dear Clifford Starke:
            This is to advise you that we do not intend to review your offering statement.
            We will consider qualifying your offering statement at your request. If a participant in
your offering is required to clear its compensation arrangements with FINRA, please have
FINRA advise us that it has no objections to the compensation arrangements prior to
qualification.
            We remind you that the company and its management are responsible for the accuracy and
adequacy of their disclosures, notwithstanding any review, comments, action or absence of action
by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of
Regulation A requires you to file periodic and current reports, including a Form 1-K which will
be due within 120 calendar days after the end of the fiscal year covered by the report.
            Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Richard Raymer, Esq.

SecProbe.io